Clay Siegall is CEO and founder of Seattle Genetics, which is a biotech firm that manufacturers targeted therapy drugs out of Seattle. Siegall has a B.S. in zoology that he obtained from the University of Maryland. He also has a Ph.D in genetics from the George Washington University.
Clay Siegall was always interested in medicine and he became interested in cancer treatment while studying zoology. When a family member had to go through chemotherapy, it really drove it home for Siegall and he figured there had to be a better way to treat cancer. Money was also a part of his interest and being your own boss definitely had appeal.
Seattle genetics earns revenues from production partnerships and from technology licensing. They became profitable only after about 10 years and despite hard times, the company managed to pull through and became quite successful.
Siegall credits his success to hard work and passion and schooling and networking also help but are secondary.
Clay Siegall is currently the Chairman, President, and Chief Executive Officer of Seattle Genetics. He previously worked for the Bristol-Myers Squibb Pharmaceutical Research Institute as well as the National Cancer Institute. Under his leadership, Seattle Genetics has obtained many licenses for its ADC technology that have generated over $350 million so far. There are over 20 ADCs in clinical development using the technology of Seattle Genetics. Siegall led Seattle Genetics to raise over $1.2 billion through various financings and continues to lead the company to great success.
Siegall is author of more than 70 publications and has over 15 patents. He has also received many awards. Siegall’s goal is to improve cancer treatment and to improve the drugs a=that are available for cancer treatment. He has been doing just that for 30 years. His advice is to learn as much as you can while you can and to interact with intelligent people.